Involvement of urokinase-type plasminogen activator system in cancer: an overview.
about
The Ins and Outs of Anthrax ToxinMechanical stretch: physiological and pathological implications for human vascular endothelial cellsCandidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitorsPET imaging of urokinase-type plasminogen activator receptor (uPAR) in prostate cancer: current status and future perspectivesModulation of CD44 Activity by A6-PeptideInhibition of urokinase plasminogen activator "uPA" activity alters ethanol consumption and conditioned place preference in mice.Colorectal cancer and basement membranes: clinicopathological correlations.Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancerAnalysis of Alpha-2 Macroglobulin from the Long-Lived and Cancer-Resistant Naked Mole-Rat and Human PlasmaHyperglycemia-suppressed expression of Serpine1 contributes to delayed epithelial wound healing in diabetic mouse corneas.Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.Analysis of soluble urokinase plasminogen activator receptor in multiple myeloma for predicting prognosis.A novel uPAg-KPI fusion protein inhibits the growth and invasion of human ovarian cancer cells in vitroDown-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions.Plasminogen activator inhibitor-1 enhances radioresistance and aggressiveness of non-small cell lung cancer cellsThe Ly49E Receptor Inhibits the Immune Control of Acute Trypanosoma cruzi Infection.Substrate Activity Screening (SAS) and Related Approaches in Medicinal Chemistry.Schwann Cells Increase Prostate and Pancreatic Tumor Cell Invasion Using Laminin Binding A6 IntegrinMacrophages of M1 phenotype have properties that influence lung cancer cell progression.Dysregulation of TTP and HuR plays an important role in cancers.Transforming growth factor-β, matrix metalloproteinases, and urokinase-type plasminogen activator interaction in the cancer epithelial to mesenchymal transition.Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.SCUBE1: a promising biomarker in renal cell cancerSerum levels of urokinase-type plasminogen activator in healthy dogs and oncologic canine patients.Caveolin-1-dependent and -independent uPAR signaling pathways contribute to ganglioside GT1b induced early apoptosis in A549 lung cancer cells.Urokinase plasminogen activator secreted by cancer-associated fibroblasts induces tumor progression via PI3K/AKT and ERK signaling in esophageal squamous cell carcinoma.The fibrinolysis inhibitor α2-antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer.State of the Art of Stimuli-Responsive Liposomes for Cancer Therapy.The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer.Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.Application of polymersomes engineered to target p32 protein for detection of small breast tumors in mice.
P2860
Q26765437-75520A85-5423-434D-A6B2-2B677E86931DQ26782873-07451D72-B921-4AF2-90A5-C2C8AB928EF3Q26830522-1473AA28-2572-4E31-9F93-B286D6AE22A9Q28078479-397BB903-0000-4C2C-A076-B5C6DF0C9C13Q28085166-D3B5201A-FA94-4852-820C-0236E66A861EQ34229752-BD0502E1-0BDE-4A26-8A79-FB0450336296Q34968207-D2C5C883-E192-4B91-8508-B7B947A1925DQ35631181-44F7D37E-1BEF-4E0C-BB91-25B3698C16DEQ35672057-18C6DF39-A806-4132-8175-AE60028C4B6EQ35678791-DF63B423-747F-43DE-B3A8-7FF936EE0CC6Q36028684-9ED696B9-E3E7-42E7-9C22-3489E54EF87BQ36085907-52943182-C4D0-46DA-82D8-75548AA20A70Q36791190-5729BE61-8251-4C7F-BBDE-8DC731904FE4Q37203214-F0B26570-52B4-4DDD-AEA0-860D04A67D4AQ37269183-2A834C6F-7D9E-411E-B235-ED85B9D6F9ACQ37406176-7070DBCD-140C-490C-82FF-CE762EB8AF29Q38722942-C6750531-F92C-413A-95CA-C6392B45502DQ38846570-B8EC26ED-4786-43AB-A340-E6A4A03F5AA4Q38866724-42338587-FAF5-4DCA-A159-292F76A5E462Q38958552-E7408720-0A28-4833-B737-32923BA9C3F2Q39443785-FC2A9C5C-7424-4933-9EF0-9FE699FFDC83Q40872425-6F244E11-8BB8-4634-982F-354F8BB5C5E4Q41412069-2293635B-8139-4448-84D5-C786328F7AE8Q41469380-434A665A-7AC3-457E-B545-9D3A3AD0BC46Q42006325-C37F7C6D-BAB8-4EB3-ACF5-4709328E4C10Q42119412-572A217A-7F8D-455C-B286-16789200157CQ50896878-665BCB12-24A0-44FE-AE31-154F94322D7DQ51738726-6CFE868A-0A37-48AD-AC74-050C3A66EA77Q53589371-644C97CC-0311-4DEB-B3C9-5114D0B5C942Q54960825-41764DE6-CF31-4106-9685-F37E2C5D2E54Q55267046-B97CCC9C-B0EC-4BEB-90D9-8195DD13A3A9
P2860
Involvement of urokinase-type plasminogen activator system in cancer: an overview.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Involvement of urokinase-type plasminogen activator system in cancer: an overview.
@en
type
label
Involvement of urokinase-type plasminogen activator system in cancer: an overview.
@en
prefLabel
Involvement of urokinase-type plasminogen activator system in cancer: an overview.
@en
P2860
P356
P1476
Involvement of urokinase-type plasminogen activator system in cancer: an overview.
@en
P2093
David L Morris
Mohammad H Pourgholami
P2860
P304
P356
10.1002/MED.21308
P577
2014-02-18T00:00:00Z